Drug delivery strategies for Alzheimer's disease treatment
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Current Alzheimer's disease (AD) therapy is based on the administration of the drugs donepezil, galantamine, rivastigmine and memantine. Until disease-modifying therapies become available, further research is needed to develop new drug delivery strategies to ensure ease of administration and treatment persistence. AREAS COVERED: In addition to the conventional oral formulations, a variety of drug delivery strategies applied to the treatment of AD are reviewed in this paper, with a focus on strategies leading to simplified dosage regimens and to providing new pharmacological tools. Alternatives include extended release, orally disintegrating or sublingual formulations, intranasal or short- and long-acting intramuscular or transdermal forms, and nanotechnology-based delivery systems. EXPERT OPINION: The advent of new research on molecular mechanisms of AD pathogenesis has outlined new strategies for therapeutic intervention; these include the stimulation of α-secretase cleavage, the inhibition of γ-secretase activity, the use of non-steroidal anti-inflammatory drugs, neuroprotection based on antioxidant therapy, the use of estrogens, NO synthetase inhibitors, and natural agents such as polyphenols. Unfortunately, these compounds might not help patients with end stage AD, but might hopefully slow or stop the disease process in its early stage. Nanotechnologies may prove to be a promising contribution in future AD drug delivery strategies, in particular drug carrier nano- or microsystems, which can limit the side effects of anti-Alzheimer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239 · cited 1×
“through the mucus layer and cross the epithelial membrane of the nasal cavity, thus bypassing the clearance mechanisms imposed by the mucociliary apparatus, the broad range of metabolic enzymes present in the nasal tissues, and the efflux transporters that reside in the apical area of ciliated epithelial cells and in…”
BackgroundThorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907 · cited 1×
“Possible mechanisms of transport of active molecules may involve a combination of axonal transport from the olfactory neurons of the olfactory epithelium to the olfactory bulb, and of extracellular transport routes involving bulk flow and diffusion within perineuronal channels and perivascular spaces or lymphatic chan…”
BackgroundOxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Nasal mucociliary clearance as a factor in nasal drug delivery
Marttin, E., Schipper, N. G. M., Verhoef, J. C., & Merkus, F. W. H. M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00059-8 · Cited by 469 · cited 1×
“through the mucus layer and cross the epithelial membrane of the nasal cavity, thus bypassing the clearance mechanisms imposed by the mucociliary apparatus, the broad range of metabolic enzymes present in the nasal tissues, and the efflux transporters that reside in the apical area of ciliated epithelial cells and in…”
BackgroundIn situ forming parenteral drug delivery systems: an overview
Packhaeuser, C. B., Schnieders, J., Oster, C. G., & Kissel, T. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.003 · Cited by 413
Cited by
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Critical evaluation of biodegradable polymers used in nanodrugs
Caballero-George, C., Marin, & Briceño (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47186 · Cited by 252
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Stys, P. K., You, H., & Zamponi, G. W. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.225276 · Cited by 115
“…regulation of NMDA receptor function NMDA receptors have been implicated in Alzheimer’s disease (AD), and the NMDA receptor blocker memantine is Food and Drug Administration (FDA) approved for the treatment of this disorder (Kalia et al. 2008; Kotermanski & Johnson, 2009; Di Stefano et al. 2011).”
BackgroundBanik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
“Delivery of therapeutic agents for most brain disorders remains a major cause of concern due to central nervous system (CNS) penetration across the bloodbrain barrier (BBB) [82, 83].”
Metadata
- Authors
- Di Stefano, A., Iannitelli, A., Laserra, S., & Sozio, P.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2011-03-11
- Volume
- 8
- Issue
- 5
- Pages
- 581-603
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2124491045
- Cited by
- 105
- References
- 15
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug delivery strategies for Alzheimer's disease treatment. https://app.cochat.ai/papers/10.1517/17425247.2011.561311
- The paper
- Di Stefano, A., Iannitelli, A., Laserra, S., & Sozio, P. (2011). Drug delivery strategies for Alzheimer's disease treatment. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2011.561311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.